Do PEMT variants reduce phosphatidylcholine synthesis and DHA transport into cell membranes?

Phosphatidylethanolamine N-methyltransferase (PEMT) activity is a critical determinant of systemic phosphatidylcholine (PC) availability, which acts as the primary metabolic precursor for transporting and incorporating docosahexaenoic acid (DHA) into target cell membranes.

Genetic impact on PC synthesis

• Enzymatic reduction: The PEMT rs7946 (V175M) loss-of-function polymorphism reduces the capacity for de novo PC synthesis from phosphatidylethanolamine by approximately 30%.
• Systemic depletion: This genetic variant diminishes endogenous PC pools and alters circulating plasma lipid profiles. While complete PEMT deficiency models exhibit a 40% reduction in circulating plasma PC, human rs7946 carriers experience a significant vulnerability to depleted hepatic PC and subsequent fatty liver development if dietary choline intake is suboptimal.

Mechanistic role in DHA transport

• Precursor hydrolysis: Intact diacyl PC-DHA cannot directly cross tightly regulated physiological barriers. It must first undergo enzymatic hydrolysis to form lysophosphatidylcholine (LPC-DHA).
• Transporter-mediated uptake: LPC-DHA serves as the primary, preferred carrier format for DHA. It is specifically recognized and transported across the blood-brain and blood-retinal barriers by the sodium-dependent transporter MFSD2A, which flips the molecule into the inner leaflet of target cell membranes. Consequently, systemic PC availability directly modulates downstream LPC-DHA production and brain DHA accretion.

Bottom line

• The PEMT rs7946 variant reduces de novo PC synthesis capacity by roughly 30%, which directly compromises the endogenous precursor pool required to generate LPC-DHA—the essential ligand for MFSD2A-mediated DHA transport and membrane integration.